Guru Sonpavde: New Study on Early Dynamics of Atezolizumab Resistance in Systemic Immunotherapy for Bladder Cancer
Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, shared a post on LinkedIn about recent paper he and his colleagues authored:
“Bladder Cancer systemic immunotherapy biomarker paper.
Problem: Pre-emptive identification of patients at high risk of primary refractory disease on any systemic therapy is challenging but necessary to enable an early switch to other treatment choices before early death, rapid clinical progression, or ineligibility for second-line therapy due to frailty or decline in performance status (molecular assays such as ctDNA are not readily available globally);
Our study: Early dynamics (baseline -> early on treatment approximately at end of cycle 1) of routinely available clinical and laboratory parameters predicted primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab- retrospective analysis of large Phase III trial of post-platinum therapy- AUC for prediction of primary refractory disease (progressive disease as best response) on atezolizumab was 0.87- our model identifies patients destined to exhibit primary refractory disease to atezolizumab before clinical progression, which may inform therapeutic decisions if further validated.
Pleased to collaborate from AdventHealth Central Florida Cancer Institute with Franziska Michor, Christopher Graser, Dana-Farber Cancer Institute.”
Title: Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab
Journal: Journal for ImmunoTherapy of Cancer
Authors: Christopher J Graser, Thomas O McDonald, Paul J Catalano, Guru Sonpavde, Franziska Michor
Read Full Article.
More posts featuring Bladder Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023